AGP Picks
View all

Anti-cancer monoclonal antibodies market seen topping $112B by 2030

Oct. 27, 2026
Anti-cancer monoclonal antibodies market seen topping $112B by 2030
By AI, Created 00:30 UTC, Oct 27, 2026, AGP -

The Business Research Company projects the anti-cancer monoclonal antibodies market will exceed $112 billion by 2030, driven by rising cancer cases, more oncology R&D and wider use of precision medicine. North America is expected to stay the largest region, while Roche remains the market leader in a concentrated field.

Why it matters: - Anti-cancer monoclonal antibodies are becoming a larger part of oncology care as treatment shifts toward targeted and biomarker-guided therapies. - The segment is forecast to exceed $112 billion by 2030, making it one of the biggest growth areas inside the broader targeted therapy market. - The category is expected to account for about 71% of the targeted therapy sector by 2030. - The market is also projected to represent close to 4% of the global pharmaceuticals industry by 2030.

What happened: - The Business Research Company published its Anti-Cancer MABs Global Market Report 2026 – Market Size, Trends, And Forecast 2026-2035. - The report projects the anti-cancer monoclonal antibodies market will grow at a 9% compound annual growth rate through 2030. - North America is projected to remain the largest regional market at $42 billion in 2030, up from $28 billion in 2025. - The United States is projected to be the largest country market at $40 billion in 2030, up from $25 billion in 2025.

The details: - Humanized antibodies are projected to be the largest product segment, with 40% of the market and about $45 billion in 2030 value. - The market covers blood cancer, breast cancer, lung cancer, melanoma, colorectal cancer, liver cancer and other indications. - End users include hospitals, research institutes and other healthcare providers. - North American growth is linked to broader use of targeted biologic therapies, rising cancer incidence, wider reimbursement for monoclonal antibody treatments, active clinical research, biomanufacturing investment and established cancer-care infrastructure. - U.S. growth is tied to more approvals for novel monoclonal antibody drugs, greater use of precision medicine, high healthcare spending, biomarker-guided therapies and ongoing immuno-oncology R&D. - The report says rising global cancer incidence should add about 2.7% to annual market growth. - Growing oncology R&D investment is expected to contribute about 2.4% to yearly growth. - Clinical success for humanized and fully human monoclonal antibodies is expected to contribute about 2.1% to annual growth. - Murine, chimeric, humanized and other antibody types are projected to add more than $40 billion in value by 2030. - Over the next five years, humanized antibodies are expected to grow by $16 billion, other antibody types by $13 billion, chimeric antibodies by $7 billion and murine antibodies by $4 billion.

Between the lines: - The market is highly concentrated, with the top 10 companies accounting for 57% of revenue in 2025. - Roche led the global market in 2025 with a 24% share. - The concentration reflects the difficulty of developing biologics, clinical and regulatory hurdles, intellectual property protection and manufacturing demands. - Competition is shifting toward bispecific antibodies, antibody-drug conjugates, biomarker-driven treatments and manufacturing improvements. - Strategic partnerships are becoming a key route to faster development and commercialization. - In October 2025, Takeda Pharmaceuticals formed a global alliance with Innovent Biologics to co-develop and commercialize IBI363, a late-stage bispecific PD-1/IL-2α antibody fusion protein, along with other oncology antibody treatments.

What's next: - Companies are expected to keep expanding oncology pipelines through bispecific antibody platforms, precision oncology programs and antibody-drug conjugates. - More collaborations are likely as firms try to speed development, widen access and compete in solid tumor indications. - Continued advances in antibody engineering and biomanufacturing should support future market growth. - The report’s updated 2026 edition adds market attractiveness scoring, TAM analysis, company scoring matrices, Excel forecasting dashboards, hotspot infographics and refreshed trend analysis.

The bottom line: - Anti-cancer monoclonal antibodies are moving deeper into the center of oncology strategy, with rapid growth, strong regional demand and intense competition among a small group of major players.

Disclaimer: This article was produced by AGP Wire with the assistance of artificial intelligence based on original source content and has been refined to improve clarity, structure, and readability. This content is provided on an “as is” basis. While care has been taken in its preparation, it may contain inaccuracies or omissions, and readers should consult the original source and independently verify key information where appropriate. This content is for informational purposes only and does not constitute legal, financial, investment, or other professional advice.

Sign up for:

Global Healthcare Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.

Share this page:

Advanced Search Options

Search for:

Search scope:

Type:

Search in:

Date range:

The last

Sort by:

Sign up for:

Global Healthcare Today

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.